Live at IDWeek 2014

EVG/COB/FTC/TDF Single Tab Improves Fasting Triglycerides in HIV Patients

Switching to single-tablet co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir (EVG/COB/FTC/TDF) from a multi-tablet ritonavir-boosted protease inhibitor (PI + RTV) with emtricitabine and tenofovir DF (FTC/TDF) regimen significantly increased rates of virologic suppression and declined fasting triglycerides in patients with HIV-1 infection.

Quadrivalent Influenza Vaccine May Improve Efficacy by Avoiding B Strain Mismatch

The investigational Intradermal (ID) Quadrivalent Inactivated Influenza Vaccine (IIV4-ID) tested in a Phase 3 clinical trial during the 2012-13 influenza season produced antibody responses to B strains that were superior to a licensed split-virion trivalent influenza vaccine (IIV3-ID) containing the alternate strain, and noninferior for the A and matched B strains.